Doer Biotech Selected for Zhejiang Province's 2025 'Jianbing Lingyan + X' Science and Technology Program with Multispecific Antibody/ADC Drug Development Project
Doer Biologics
Biological Drug Developer
On November 26, 2024, the Zhejiang Provincial Science and Technology Department announced the list of proposed projects for the 2025 "Pioneer Leader + X" Science and Technology Plan. Doer Biologics' research project, "Development of Multi-Specific Antibodies/ADC Drugs," was successfully selected for the "New Antibody Drug Development" category under the "Pioneer Leader + X" initiative.
Zhejiang Province's "Pioneer" and "Leader" R&D Challenge Plan, established by Zhejiang provincial fiscal funds, is a scientific and technological plan aimed at addressing cutting-edge scientific issues in key technology areas. It focuses on the frontiers of global science and technology, the main economic battlefield, major national and Zhejiang-specific demands, and the health of the people. The plan supports research activities such as frontier scientific problem studies in key technical fields, major core technology breakthroughs, significant social public welfare research, and major international scientific and technological cooperation.
Among them, the "Pioneer" plan focuses on the major scientific and technological strategic goals of China and Zhejiang Province. It centers on key core technologies, strategic frontier technologies, major strategic products, and major projects. The plan adheres to a full-chain innovation design and integrated organization and implementation, pooling scientific and technological resources and concentrating superior forces to carry out large-scale operations.
Doer Biologics' successful inclusion of the "Multispecific Antibody/ADC Drug Development" project in the "Pacesetter + X" Science and Technology Plan reflects the high recognition from the leadership and experts of the Zhejiang Provincial Department of Science and Technology for the company's technical R&D capabilities and potential. Doer Biologics expresses its gratitude to the Zhejiang Provincial Department of Science and Technology for their continued funding, which helps the company adhere to innovative development and continuously enhance its core competitiveness. In the future, the company will continue to focus on innovative drug R&D, balancing independent research with open collaboration, accelerating the R&D process, and living up to the trust and support of the Zhejiang Provincial Department of Science and Technology by bringing safer and more effective innovative biologic drugs to patients worldwide.
Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics") is a clinical-stage biopharmaceutical company focused on the discovery and development of multi-specific biotherapeutics based on multi-domain structures to address unmet medical needs in the fields of metabolic diseases and cancer.
Doer Biologics has developed a variety of proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody.
For more information about Doer Biologics, please visit www.doerbio.com